JT-003
- Generic Name
- JT-003
To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 245
- Registration Number
- NCT05296044
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath